exhibit 10. 22 confidential materials omitted and filed separately with the securities and exchange commission. asterisks denote omissions. amendment one to the exclusive license ( cmcc - 10665 ) this amendment is made and entered into as of may 12, 2011 ( the “ amendment ” ) by and between children ’ s medical center corporation, a corporation duly organized and existing under the laws of the commonwealth of massachusetts and having offices located at 300 longwood avenue, boston, ma ( “ cmcc ” ) and invivo therapeutics corporation, a business corporation organized and existing under the laws of the state of delaware and having its principal office at one broadway, 14th floor, cambridge, ma “ licensee ” ). whereas, cmcc and licensee have entered into that certain exclusive license agreement with an effective date of july 2, 2007 and identified as agreement number cmcc - 6748 ( the “ agreement ” ) ; whereas cmcc and licensee wish to amend such agreement through this amendment ; and whereas the agreement otherwise remains unchanged. in consideration of these premises and of the mutual promises set forth below, the parties agree to amend the agreement as follows : amendments to the agreement : 1. article i. definitions, paragraph f of the agreement, “ field of use ”, is hereby deleted in its entirety and replaced as follows : f. “ field of use ” shall mean the following three subfields : i ) treatment of nerve injury of the central nervous system including the brain, and spinal cord ; ii ) treatment of nerve injury of the retina and the cranial nerves ; and iii ) treatment of the following pathologic conditions : nerve root impingement from musculoskeletal elements, demyelinated tissue, damage to neural elements exiting the spinal cord and lumbosacral region of spinal cord by administering a licensed product to the peripheral nerves in the intraspinal location, foraminal and extraspinal areas, extrapyramidal regions, areas of peripheral bony impingement, and for repair or treatment of neural elements following damage from prostate surgery ; excluding the development and commercialization of tissue engineered products for human and animal therapeutics in the field of genitourinary. 2. in consideration for expanding the field of use, licensee shall pay to cmcc a license amendment fee of $ [ * * * * ] within thirty ( 30 ) days of the full execution of this amendment in addition to any other payments due under the